

Message

From: Elizabeth Holmes [/O=THERANOS ORGANIZATION/OU=FIRST ADMINISTRATIVE GROUP/CN=RECIPIENTS/CN=EHOLMES]
Sent: 10/14/2014 4:51:06 AM
To: Daniel Edlin [/O=THERANOS ORGANIZATION/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=Daniel Edlin]
Subject: RE: AFRICOM: Temperature Data, Correlation Slides, Theranos Overview Information Previously Sent

Yes. Print out the package for me to glance at this week and we will do that.

From: Daniel Edlin
Sent: Monday, October 13, 2014 9:48 PM
To: Elizabeth Holmes
Subject: RE: AFRICOM: Temperature Data, Correlation Slides, Theranos Overview Information Previously Sent

Unfortunately we did not, we couldn't reach a consensus on what the 'temperature data' would be and at the time we did not have all of the assay development/validation data to send.

I'd be happy to reconnect on this...our Ebola work could be a natural impetus to reengage with Missy.

From: Elizabeth Holmes
Sent: Monday, October 13, 2014 9:05 PM
To: Daniel Edlin
Subject: RE: AFRICOM: Temperature Data, Correlation Slides, Theranos Overview Information Previously Sent

Did we ever get this out

From: Daniel Edlin
Sent: Saturday, October 12, 2013 4:18 PM
To: Elizabeth Holmes
Subject: FW: AFRICOM: Temperature Data, Correlation Slides, Theranos Overview Information Previously Sent

Hi Elizabeth,

Wanted to resend this AFRICOM information for review so we can get this out to Missy. To recap, this information would be sent to MEDCOM and IRB for the purpose of generating a future research protocol. This is from Missy in a previous email:

-I am trying to sort out the hiccups with MEDCOM and come up with a way ahead on my research protocol so more to follow on that effort. Any sort of summary you can give me on CLIA/FDA issues would be helpful. Also any published correlation data of specific laboratory assays would help me to get the project past the IRB.

I do not want to duplicate your work with SOCOM and CENTCOM so I am trying to reach out to those organizations so we do not double tap you for information. Gen Hamm remains interested in supporting your product so I would like to move ahead before he changes command.

-Could you please send me the QA data from the samples I ran this past summer in Cameroon and Uganda? I can use this data to strengthen my IRB proposal.

Please find attached:

- Updated deck with the latest and greatest clinical slides. Remaining assays from the program protocol that we still do not have are as follows:
 - Anion Gap
 - Hematocrit
 - Malaria antigen test
 - Malaria PCR Test
 - Myoglobin
 - *Troponin I – we have this clinical correlation however the $R^2 = 0.89$
- Theranos Overview Information Previously Sent – includes ppt deck, overview word document, and a regulatory overview document
- Temperature data from the ppt presentations we previously reviewed
- Temperature data from Daniel, Gary, and Tim
- Demo/Survey Results for each patient tested

I'll drop by to discuss.

Thanks,

Dan

From: Daniel Edlin

Sent: Monday, June 10, 2013 9:49 PM

To: Elizabeth Holmes

Subject: FW: AFRICOM: Temperature Data, Correlation Slides, Theranos Overview Information Previously Sent

Hi Elizabeth,

Attached are all of the materials previously sent as well as one new temperature document from Tim.

Thanks,

Dan

From: Daniel Edlin
Sent: Monday, April 08, 2013 9:28 PM
To: Elizabeth Holmes
Subject: AFRICOM: Temperature Data, Correlation Slides, Theranos Overview Information Previously Sent

Hi Elizabeth,

Please find the following attached. This should depict the full overview of the AFRICOM project:

- Temperature data from the ppt presentations we previously reviewed
- Temperature data from Daniel, Gary, and Tim
- Theranos Overview Information Previously Sent
- o Do we have any update to share on CLIA/FDA status? LTC Givens had indicated that her supporting lab would need more information on this.
- Clinical Correlation Slides
- o Development timeframes for the non-finished assays are as follows:
 - D-Dimer about 1-2 weeks of development to go
 - Hematocrit <1 week
 - Malaria Antigen at least 1 month of development to go
 - Malaria PCR not being worked on at this time
 - Myoglobin not being developed on at this time
 - Troponin I ~ 1-2 weeks of development to go
- o I am meeting with teams tomorrow to discuss how to improve the r2 values for CK-MB (0.87), HDL-Chol (0.81) and Total Protein (0.89)

- Also – we are holding a meeting tomorrow with Sunny to review the Theranos web portal so we can start the redesign.

Please let me know if you have any questions on the above.

Thanks,

Dan

From: Daniel Edlin
Sent: Thursday, March 28, 2013 10:59 PM
To: Elizabeth Holmes
Subject: RE: Temperature Data - AFRICOM + Feedback on Edison Results

Attached is the compilation of what we reviewed last night. Slides 17-20 seem similar to what we just discussed.

From: Daniel Edlin
Sent: Thursday, March 28, 2013 8:56 PM
To: Elizabeth Holmes
Subject: Temperature Data - AFRICOM + Feedback on Edison Results

Hi Elizabeth,

- 1) Please find attached the temperature plots for the 10 tests.
- 2) I asked Daniel, Gary, Tony, and Gary if they had data around our devices maintaining internal temperature while exposed to high outside temperature. The feedback is as follows:

Daniel:

- (Has not had any data yet; I've asked again and am waiting to hear back)
- Question from Daniel: How high are the temperatures you are referring to?

Gary:

- “Nope, the Edison did not have a way to cool down. They would have shut down.”

Tony:

- “The Edison 3.0 for various reasons operates in a fairly narrow indoor ambient temperature range of 22 to 28 degrees C. 72 to 82 degrees F.
 - Lower than this required too long to reach internal operating temperature (34 degrees C)
 - Higher than this, we have no way to cool the device.
 - Experiments were conducted to increase the range below, by developing a cover for the device for colder climates (insulation), or a special box its operated within for example.
 - Experiments to increase it involving a cooling cover using a product that's used to keep insulin syringes cool with water evaporation were also conducted. A cool box was also considered.
 - Since development moved on to the 4... series these were not pursued further.”

Surekha:

- “Many years ago we would have problems with the readers working due to poor A/C in the labs during summer and there were reported problems of the readers achieving run temperatures in cold places.”

Please let me know if you have any questions.

Thanks,

Dan

Daniel P. Edlin

Senior Product Manager

Theranos, Inc.

Office: 650.470.0322

Mobile: 650.701.473

PRIVILEGED AND CONFIDENTIAL COMMUNICATION

IMPORTANT -- This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which they are addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

Theranos, Inc., 1601 S. California Avenue, Palo Alto, CA, 94304

650-838-9292 www.theranos.com